Evercore Upgrades Cardinal Health(CAH.US) to Buy Rating, Raises Target Price to $140

Evercore上調卡地納健康(CAH.US)至買入評級，上調目標價至140美元

moomoo資訊 · 01/07 19:31 · 評級/大行評級

Evercore analyst Elizabeth Anderson CFA upgrades $Cardinal Health (CAH.US)$ to a buy rating, and adjusts the target price from $130 to $140.

According to TipRanks data, the analyst has a success rate of 37.7% and a total average return of -7.6% over the past year.

AnalystRecentRatingAutoNews_201932_20250107_6a8f23bc048d784b18332e579f16f374da6379f3_1736335837125593_mm_en

Furthermore, according to the comprehensive report, the opinions of $Cardinal Health (CAH.US)$'s main analysts recently are as follows:

Cardinal Health has started to exhibit organic growth in the core pharma segment, surpassing its competitors. This performance is anticipated to outperform market expectations in the coming year. The notable expansion stems from gaining new customers and retaining existing ones, alongside a distinct PBM tailwind that could potentially enhance EPS growth by 2-3 percentage points through FY26.
The belief that new customers, strong utilization trends, and recent acquisitions into specialty services will contribute to Cardinal Health achieving adjusted earnings growth exceeding current expectations and generating Pharma segment growth above its 4%-6% long-term target.
The updated guidance suggesting only about 4% adjusted operating income growth for the remainder of FY25 has been deemed conservative, as there appears to be potential for surpassing Cardinal Health's long-term forecasts. Furthermore, the earnings per share for FY25 are likely to exceed expectations, with FY26 anticipated to mark a return to Cardinal's historical compound annual growth rate of 12%-14%.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Evercore分析師Elizabeth Anderson CFA上調$卡地納健康 (CAH.US)$至買入評級，並將目標價從130美元上調至140美元。

根據TipRanks數據顯示，該分析師近一年總勝率為37.7%，總平均回報率為-7.6%。

AnalystRecentRatingAutoNews_201932_20250107_6a8f23bc048d784b18332e579f16f374da6379f3_1736335837125593_mm_tc

此外，綜合報道，$卡地納健康 (CAH.US)$近期主要分析師觀點如下：

Cardinal Health已開始在覈心製藥領域表現出有機增長，超過了競爭對手。預計來年的表現將超過市場預期。顯著的擴張源於獲得新客戶和留住現有客戶，以及明顯的PbM利好勢可能會在26財年之前將每股收益增長2-3個百分點。
相信新客戶、強勁的利用率趨勢以及最近對專業服務的收購將有助於Cardinal Health實現超過當前預期的調整後收益增長，並使製藥板塊的增長超過其4％-6％的長期目標。
最新的指導方針表明，25財年剩餘時間調整後的營業收入增長僅爲4％左右，這被認爲是保守的，因爲似乎有可能超過Cardinal Health的長期預測。此外，25財年的每股收益可能超出預期，預計26財年將標誌着Cardinal恢復12％-14％的歷史複合年增長率。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Evercore Upgrades Cardinal Health(CAH.US) to Buy Rating, Raises Target Price to $140

Evercore Upgrades Cardinal Health(CAH.US) to Buy Rating, Raises Target Price to $140

風險及免責聲明

聲明